12:00 AM
 | 
Feb 07, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Nevanac nepafenac regulatory update

Alcon disclosed in its 4Q10 earnings that it submitted an MAA to the European Medicines Agency (EMA) for Nevanac nepafenac to prevent...

Read the full 88 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >